1. Home
  2. KN vs SNDX Comparison

KN vs SNDX Comparison

Compare KN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knowles Corporation

KN

Knowles Corporation

HOLD

Current Price

$22.52

Market Cap

1.8B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KN
SNDX
Founded
1946
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
KN
SNDX
Price
$22.52
$20.82
Analyst Decision
Buy
Strong Buy
Analyst Count
3
12
Target Price
$22.33
$36.92
AVG Volume (30 Days)
657.5K
2.1M
Earning Date
10-23-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
$573,500,000.00
$111,304,000.00
Revenue This Year
$9.26
$620.14
Revenue Next Year
$5.87
$115.42
P/E Ratio
$47.94
N/A
Revenue Growth
4.24
595.65
52 Week Low
$12.19
$8.58
52 Week High
$24.54
$21.22

Technical Indicators

Market Signals
Indicator
KN
SNDX
Relative Strength Index (RSI) 46.23 67.42
Support Level $23.19 $20.00
Resistance Level $24.18 $21.22
Average True Range (ATR) 0.61 0.93
MACD 0.06 0.02
Stochastic Oscillator 28.76 85.90

Price Performance

Historical Comparison
KN
SNDX

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: